Erfan Media

Candidate Records / Rick Jackson / Medicare En español

Rick Jackson on Medicare: Ending Coverage for Some Enrollees, Help With Premiums, and Higher Drug Costs in the Law He Backs

Rick Jackson, the Republican nominee for governor of Georgia, supports the One Big Beautiful Bill Act; his campaign told Fox News on April 27, 2026 that he supports the bill, "Period." The law ends Medicare for some lawfully present immigrants on February 1, 2027, the first time Congress has taken Medicare away from people who were legally eligible, according to KFF.

The same law blocks two rules that would have made it easier for low-income seniors to get help paying their Medicare premiums, and exempts more drugs from Medicare price negotiation, at a cost to Medicare of $8.8 billion. About 1.9 million Georgians are enrolled in Medicare.

Rick Jackson's Support for the Law's Medicare Changes

What the Medicare Changes Rick Jackson Supports Mean for Georgia Seniors

Frequently Asked Questions About Rick Jackson on Medicare

What is Rick Jackson's record on Medicare under Trump?

Rick Jackson's campaign said in April 2026 that he supports the One Big Beautiful Bill Act without qualification. That law ends Medicare for about 100,000 lawfully present immigrants, blocks rules that help low-income seniors pay Medicare premiums, and costs Medicare $8.8 billion by exempting more drugs from price negotiation. Its tax changes also bring forward the date Medicare's hospital fund runs short.

Will people lose Medicare under the law Rick Jackson supports?

Yes. Under the law Rick Jackson supports, refugees, people granted asylum and other lawfully present immigrants who are not green-card holders lose Medicare, and the Social Security Administration is sending termination notices in late December 2026 for coverage ending February 1, 2027, according to the Center for Medicare Advocacy.

Does the law Rick Jackson supports affect Medicare drug prices?

Yes. Rick Jackson supports a law that delays or blocks Medicare price negotiation for some high-spending drugs used for rare diseases and cancer, including a delay of at least one year for the cancer drug Keytruda. KFF estimates that a typical negotiated discount on Keytruda would save Medicare patients who use it around $3,300 a year in cost sharing.

Last updated: 2026-10-26

Candidate Records